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The vasculature is one of the ﬁrst organ systems to develop and it
forms an extensive network throughout the body mediating gas ex-
change, transport of nutrients and waste products, as well as delivering
cells and mediators involved in immunity. Blood vessels mainly consist
of endothelial cells (ECs) that line the internal surface of the entire vas-
cular system and mural cells, i.e. vascular smooth muscle cells (VSMCs)
and pericytes, which surround the inner endothelial lining [1]. VSMCs
circumferentially wrap around the inner layers of arteries, arterioles,
veins and venules. The number of VSMC layers differs with the calibre
and speciﬁcation (venous or arterial) of the vessels. Pericytes are locat-
ed in microvessels: capillaries, in which one or two ECs make up the
inner perimeter of the blood vessel, precapillary arterioles and
postcapillary venules [1, 2]. In larger vessels, ﬁbroblasts and matrix
form an additional outer layer [1], which also contains a microvascular
system: the vasa vasorum. Moreover, bone marrow-derived circulating
cells can adhere to and/or inﬁltrate into the different layers of blood ves-
sels [1]. Several vascular and inﬂammatory cells are differently involved
in the maintenance of the integrity of blood vessels, and in vascular
remodelling following disease or injury. In post-natal life, the growth
potential of large vessels is mostly limited to development of collaterals
following the obstruction of a large vessel or a vascular shunt [3].
Classically speaking, the microvasculature network can grow through
angiogenesis (i.e., formation of small vessels from a pre-existing vascu-
lar structure) or vasculogenesis (deﬁned as the de novo formation of
blood vessels starting from stem cells). However, stem and progenitor
cells are nowknown to contribute to both vasculogenesis and angiogen-
esis. For the former, they can differentiate into vascular cells which
represent the building blocks of new vessels. For the latter, they can
act in a paracrine manner (i.e., releasing proangiogenic factors) to
promote angiogenesis. The vascular biology community started to use
the term “post-natal vasculogenesis” when evidence of the existence
of “endothelial progenitor cells” able to integrate in blood vessel struc-
ture were proposed by Asahara and others [4,5] in the late 90s. Today,
this term is not commonly used and “angiogenesis” is widely employed
to describe the post-natal growth of microvessels.
A healthy and functional vasculature is essential to ensure tissue
perfusion. Congenital and acquired vascular diseases create the need
for surgical anatomical repair, endarterectomy and by-pass or replace-
ment of (portions of) large vessels. The possibility to use portions of
autologous vessels is limited in some patients, due to extensive athero-
sclerosis disease, previous harvest or insufﬁcient time to proceed with
harvest (such after aneurysm rupture). Biological homografts, xeno-
grafts and prosthetic grafts are currently used in the operating theatre,
but they present some limitations, especially as substitute for smaller
vessels such as coronary arteries and the lower leg and foot arteries
where limited run-off (distal ﬂow rate) is a signiﬁcant determinant of
ﬂow rate and long-term patency. Moreover, in the context of paediatric
surgery, they have themajor limitation of not being able to remodel and
grow in synchrony with postnatal cardiothoracic development. Hence,
VTE, based on the use of (bio) materials that can be combined with
stem cells and other cellular and molecular products, is currently
being investigated as a revolutionary option that would meet these
clinical needs. Vascular pathology does not only relate tomacrovascular
disease. It also affects the microcirculation, which can worsen tissue
ischemia induced by obstruction of large arteries. Moreover, there are
clinical situations where microangiopathy can cause tissue ischemia
independently of arterial occlusion. Diabetes mellitus is one of the
main causes of microangiopathy. New therapeutic solutions thatwould enable improved blood perfusion by enhancing themicrocircula-
tion in ischemic tissues are the object of intense basic and clinical
research. Gene- and cell-based therapeutic neovascularization has
been developed for more than 20 years and is now ready to deliver
clinical success. The ﬁeld has been reviewed in many articles [6–9]
and we will not treat this broadly, limiting discussion to the potential
impact of microRNA (miR) targeting on it.
For both VTE and therapeutic angiogenesis, optimally functional
vascular cells are required and researchers are working to develop
protocols that enable improved performance of fully differentiated
cells and increase the production and quality of vascular cells from
stem and progenitor cells. An obvious approach to improve cell quantity
and quality is to manipulate the molecular pathways controlling the
regulatory processes contributing to cell survival, growth and cell
phenotype. MiRs have the capacity to modulate relevant molecular sig-
nalling through post-transcriptional inhibition of multiple target genes.
Importantly, the expressional manipulation of relevant miRs has been
shown to induce stem cell differentiation into vascular cell lineages
[10] and promote angiogenesis (reviewed in [11]).
In this article, we discuss the clinical needs and state-of-the-art
approaches for VTE and therapeutic angiogenesis; we summarize the
most relevant information on miRs involved in vascular biology and
stem cell differentiation to vascular lineages and we propose how miR
targeting could be used to improve VTE and to promote therapeutic
angiogenesis. We also discuss the remaining obstacles toward clinical
translation.
2. The clinical needs for vascular tissue engineering and therapeutic
angiogenesis
2.1 . Congenital heart defects
Congenital heart disease (CHD) includes different anatomical
defects in the thoracic vessels and/or in heart vessels and chambers.
Overall, it affects approximately 1% of all live births, making it the
most common birth defect worldwide. The most complicated CHD
cases require surgical correction using prosthetic replacement grafts in
the form of conduits and patches. However, these prosthetic materials
lack growth potential. Consequently, as the infant grows over time,
multiple operations are needed to remove the previous graft and im-
plant a new one to ﬁt the larger cardiovascular system. Improvements
in cardiac surgery techniques and use of better prosthetic materials
have led to a remarkable improvement in early survival rate with a
parallel increase in the number of patients with adult CHD [12, 13].
It has been variably estimated in the United States that between
800,000 and 1 million CHD patients are now adults and many will re-
quire some form of vascular conduit or valve replacement due to failure
of their previous grafts [14]. It is therefore necessary to develop new
modalities for the treatment of neonatal vascular and cardiac defects
to reduce or remove the need for multiple surgeries. From the above,
it is understandable why CHD surgeons look at VTE with the hope of
creating living scaffolds to be implanted as vascular conduits, valves or
patches that are able to grow together with their paediatric patients.
2.2. Arterial aneurysms
Abdominal and thoracic artery aneurysms develop from the com-
bined effect of luminal pressure and weakening of the arterial wall.
The most common site for aneurysm formation is in the infra-renal
abdominal aorta. In the United Kingdom, the prevalence of abdominal
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aaa.screening.nhs.uk/statistics)[15]. The prevalence of thoracic aneu-
rysms has been estimated of circa 1 per 10,000 people in the United
States. However, the most lethal aneurysm site is in the thoracic aorta.
In the United States, more than twice as many deaths are attributed to
thoracic aortic dissections than to abdominal aortic aneurysms [16]. In
fact, 95% of thoracic aneurysms present as an acute event (either as
rupture or dissection) without previous symptoms [17, 18]. In many
other patients, arterial aneurysms are incidental ﬁndings and are
asymptomatic until rupture. These patients can be offered prophylactic
vascular repair when their ﬁtness and the size of the aneurysm shows
the likely beneﬁt from this intervention. The current options for repair
are either open surgery with a prosthetic inlay/interposition graft or
endovascular repair with radiological placement of a stent graft. This
group of patients who harbour signals for a silent killer would greatly
beneﬁt from effective therapeutic options capable of preventing
the progression of the aneurysmal dilatation before a more invasive
intervention becomes the only possible treatment.
The embryology of the thoracic and abdominal aorta is different, as is
the aetiology of the aneurysm formation [19]. The abdominal aortic
pathology is a degenerative condition, related to age and traditional
atherosclerotic risk factors. Pathologically, extracellular matrix destruc-
tion with VSMC apoptosis and increased inﬂammatory inﬁltration is
observed. Thoracic aortic aneurysms have a stronger association with
elastin degradation and VSMC proliferation [20]. At a more advanced
stage of VTE development, the differences in the pathological features
and the underpinning upstream regulatory pathways between these
pathologies may have to be considered.
2.3. Ischemic disease
Ischemic disease in the heart and limbs is amain clinical need affect-
ing large patient populations. In this clinical context, a combination of
VTE for replacing the most severely affected or difﬁcult-to-access-and-
treat arterial vessels (usually those of smaller calibre) and stimulation
of angiogenesis in the ischemic area could be synergic to improve
clinical outcomes. MiRNA targeting could come in focus for improving
both approaches.
Ischemic heart disease (IHD) is characterized by reduced blood
supply to the heart caused by coronary artery disease (CAD), i.e. athero-
sclerosis in the coronary arteries. Diabetes mellitus (DM) heavily con-
tributes to the prevalence and severity of IHD through aggravation of
atherosclerosis and induction of microvascular disease [21]. Moreover,
DM compromises the potential for native neovascularization responses
to ischemia [21]. IHD is a leading cause of morbidity and mortality
worldwide. IHD patients often qualify for revascularization by coronary
artery bypass graft (CABG) surgery. Every year, around 28,000 CABG
procedures are performed in the UK (15–20% in patients with DM)
(from bluebook.scts.org -Blue Book Online-Society for Cardiothoracic
Surgery). The vessels commonly used for by-pass are the internal
thoracic artery (aka “internal mammary artery”) and the long saphe-
nous vein. Unfortunately, in 10 to 20% of patients full revascularization
is not always possible due to aggressive disease (calciﬁcation), small
target vessels or diffuse distal vessel disease [22]. VTE could provide a
new therapeutic hope for these “no option” patients.
VTE could be also a potential option in patients with end-stage
peripheral arterial disease (PAD). PAD affects 1 in 5 of the population
over 60 years of age (incidence in population estimate 50–100 per
100,000). Rest pain, ulceration or tissue necrosis deﬁne a situation
when PAD has progressed to critical limb ischemia (CLI), which puts
the patients at risk of losing their leg. Surgical bypass of the affected
iliac or femoral artery are possible therapeutic options for these
patients. Autologous veins that are more durable are preferred to pros-
thetic conduits in cases where bypass is performed below the knee
level. Current state-of-the-art in peripheral vascular surgery is (when
possible) the use of autologous veins taken from a leg (saphenousvein) or arm (cephalic or basilic veins). When autologous conduits are
not available, synthetic grafts made or either gelatin coated Dacron or
expanded PTFE can be used. However, the patency rates of synthetic
grafts are inferior to autologous conduits [23]. Hence, the majority
of these patients have delayed amputation due to failure of revascular-
ization. New VTE protocols producing vascular conduits with a good
patency proﬁle would represent a signiﬁcant improvement.
While revascularization (with either autologous naïve pieces of
arteries or veins, prosthetic material or bioengineered vessels) focuses
on restoring arterial blood ﬂow, therapeutic angiogenesis seeks to im-
prove the microcirculation by stimulating new blood vessel formation.
Increasing numbers of “proof-of-concept” studies in small animal
models of ischemia point to therapeutic angiogenesis as a way to
improve myocardial and limb perfusion. Evidence from these studies
fuelled the concept that molecular and cellular therapies able to stimu-
late angiogenesis could aid therapy optimization and even represent an
alternative option for those ischemic patients who are not eligible for
revascularization. Nevertheless, further work is needed to achieve the
clinical success of therapeutic angiogenesis. In view of recent literature
from our groups and others (reviewed in [24]), we propose that miR
targeting could enable further progress in the translation of therapeutic
angiogenesis to clinical practice.
3. Prosthetic materials clinically approved for large blood
vessel repairs
Themost commonmaterials used for patch reconstruction of vascu-
lar and cardiac defects in neonates and infants born with CHD include
various form of knitted polyester (most commonly Dacron), expanded
polytetraﬂuoroethylene (such as Gore-Tex®), and several types of
xenografts and homografts. The use of these vascular conduits is quite
satisfactory in large diameter applications. However, they perform
poorly in smaller vessel replacement. The blood-contacting surface
and the biomechanical properties of the graft are believed to be
important variables in causing patency in small vessels. Acellular or
decellularised scaffolds have proved useful, as they provide the natural
cues needed for recipient's cells to grow on the scaffold in terms of me-
chanics and composition [25] and it has been shown that the extracellu-
lar matrix (ECM) can still support cell growth even though many of its
components have been disrupted [26, 27]. It is hard to remove 100% of
cytoplasmic debris and nuclear materials from a biological scaffold
and the consequence of remaining material in terms of host response
remains unclear [28]. Early data indicated that decellularization of ani-
mal tissues is capable of producing stable vascular conduits that exhibit
long-term functionality in other species [29]. However, the subsequent
clinical experience has been disappointing [30], with severe degenera-
tion of the grafts after only one year from implantation.Macroscopically
these grafts showed severe inﬂammation and degeneration of the wall.
Histology demonstrated severe foreign body type reaction; and signiﬁ-
cant calciﬁc deposits were demonstrated [30]. No cell repopulation of
the animal matrix occurred [30]. It is thought that the strong inﬂamma-
tory response in humans may be due to matrix immunogenicity being
conserved or may indicate insufﬁcient decellularization to remove all
xenoantigens [30]. Other forms of vascular grafts include decellularised
tubular organs. Examples include porcine aorta, common carotid and
iliac arteries [31–33]. Among gluteraldehyde-ﬁxed xenografts, bovine
and porcine pericardial patches have been widely used by CHD sur-
geons for vascular and intra-cardiac reconstruction. More recently,
decellularised porcine small intestinal submucosa ECM has also been
employed in the clinic [34, 35]. These biological materials have many
technical merits, including easy handling and less suture bleeding
compared with the synthetic patches. They are also greatly biocompat-
ible, derived from a biological material that is ﬁxed in glutaraldehyde,
increasing the strength and stability of the material, while decreasing
antigenicity and potential infections. However, these materials have
also signiﬁcant drawbacks, including limited ability to remodel or
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formation, restenosis (especially in small vessels), ﬁbrosis and calciﬁca-
tion that can lead to graft failure and the need for re-intervention by the
surgeon. From all the above, it is clear that the “ideal” replacement vas-
cular graft, which should be durable, biocompatible, non-immunogenic,
non-thrombogenic, readily available, easy to handle, and have the
potential to grow and remodel in vivo, does not yet exist.
4. Vascular tissue engineering
Tissue engineering (TE) involves seeding cells in three-dimensional
matrices to form living tissue products having structural and functional
properties that can be used to restore, maintain or improve tissue
function. Success depends on the right combination of cells, a scaffold
(either biologic or a synthetic material), and the necessary signals. TE
approaches directed to building vascular conduits promise to overcome
the limitations of the vascular grafts currently used in clinical applica-
tions. Moreover, the utilization of matrices already approved for clinical
application could help to fast-track the translation of the tissue
engineered product to patient's bedside.
Vascular ECs andmural cells (VSMCs and pericytes) are the essential
components in vascular architecture and hence essential building
blocks for vascular tissue engineering (VTE) [36]. These vascular cells
can be obtained starting from differentiated blood vessels or through
the differentiation of stem and progenitor cells. The latter process
could be ﬁnalized before or after cells are seeded in the scaffold and
even after scaffold implantation. Themechanical properties of the vessel
are mainly driven by the VSMCs, which are also the numerically
predominant cell population. In order to maintain vascular patency
and sustain blood ﬂow, the VSMCs should be in their non-proliferative
and contractile status, which requires a correct interaction with the
intra-luminal EC layer [37]. Moreover, a healthy and continuous endo-
thelium layer ensures the right degree of interaction with and response
to intra-luminal circulating cells and subcellular components, which
is important in maintaining vascular integrity, avoiding vascular wall
inﬁltration by inﬂammatory cells and intravascular thrombosis.
For any TE approach, ideally cells should be autologous or non-
immunogenic and easy to acquire and culture in a clinical-grade
manner. Table 1 summarizes the cell types previously employed by
VTE scientists. ECM is essential for ensuring the mechanical properties
that are critical to the function of the engineered blood vessel and
hence it represents another essential ‘ingredient’ for VTE. The search
for optimal sources of cells that are readily available, with shorter and
easier culture times and good ECM production is still ongoing. A
complete biological tissue engineered blood vessel was ﬁrst produced
by Weinberg and Bell using cultured mature VSMCs and ECs in bovine
collagen gels [38]. Although this graft structurally mimicked a native
artery, it was not functional due to very low burst pressure. From then
on signiﬁcant efforts have been put into engineering vascular grafts
that mimic native vessels in composition and mechanical properties.
The approaches that have been established to date still require long
culture times and have shown varying degrees of success [39–42].
Even so, even the most successful attempts are still unsatisfactory,
failing to meet the criteria for use in clinical practice. Therefore, there
is large scope for improving the process by acting at different steps. In
this article, we focus on micro RNA (miR) targeting as a possibility toTable 1
Cell types employed in the vascular tissue engineering approaches trialled in the clinics.
Cell type and source Applic
Autologous ECs derived from the external jugular vein and cephalic vein Saphe
Autologous vascular cells derived from peripheral vein biopsies Pulmo
Autologous BM-MNC derived from iliac crest EC-TC
Autologous ﬁbroblasts and endothelial cells isolated from skin and vein biopsies Arteri
Autologous bone marrow stem cell-derived EC and VSMC Extra-
BM-MNC: bone marrow mononuclear cells; EC: endothelial cells; EC-TCPC: extracorporeal totaimprove VTE, which includes acting at the level of cell production and
on determining the type and quantity of growth factors (GFs) and
ECM in the scaffold. Given the very short half-life of exogenously
added GFs, it might be desirable to engineer the cells to increase their
production in the scaffold [43]. SomemiRs have been shown to regulate
the expression of GF and their receptors in vascular cells [44, 45]. Hence,
targeted miR therapeutics may provide an approach toward this goal.
The ECM is mainly composed of ﬁbronectin, laminin, collagens, elastin
and hyaluronic acid and provides a structural framework to support
cellular function and regulate cellular behaviour, including adhesion,
proliferation, migration and differentiation of vascular cells through
both cell-to-cell and cell-with-matrix interactions. Integrins and several
proteases, especially matrix metalloproteinases (MMPs) regulate these
processes, impacting on matrix remodelling and stiffness [43]. It is
therefore conceivable that, as described below, modulating the expres-
sion of miRs to control ECM function in vascular cells or vascular pro-
genitor cells before or after cell seeding into the scaffold might help to
improve the properties of ECM and ultimately of the cell-engineered
vascular graft.
5. microRNAs controlling vascular biology and the differentiation of
stem cells to vascular lineages
5.1. MicroRNA biogenesis and mechanism of actions
MiRs are endogenous small non-coding (nc) RNAs. MiRs are
encoded by autonomous miR genes or intronic sequences embedded
in protein coding genes. A large proportion of miRs are clustered in
polycistronic units. The canonical miR biogenesis for autonomous miR
genes starts with RNA polymerase II-mediated transcription, producing
a primary miR (pri-miR) of variable length. This is followed by pri-miR
cleavage by a nuclear RNase complex, Drosha/DGCR8, generating a
precursormiR (pre-miR) that has a hairpin-like secondary structure [46,
47]. Next, the pre-miR is translocated out of the nucleus to either the cy-
toplasm or the rough endoplasmic reticulum (ER) and subject to further
enzymatic processing by the RNAse Dicer and its cofactors, producing a
≈22 nucleotide long double strand composed by two miR sequences
[46, 48–51]. One or both strands of the duplex can be recruited into
the RNA-induced silencing complex (RISC), a RNA-protein complex
that contains Dicer, other RNA binding proteins and Argonaute (Ago)
proteins and that enables themiR to repress the expression of its “target
genes” [52]. AmiR recognizes itsmRNA targetsmostly through its “seed
sequence” of 8 nucleotides, located in the miR 5′ untranslated region
(5′-UTR) sequence which is (semi)complementary to one or more
miR binding sites in the mRNA 3′-UTR. The end result of miR action is
the repression of protein production from its targeted mRNAs. This
can be reached through miR-induced mRNA degradation, transcript
deadenylation, inhibition of translation, or sequestration of the mRNA
in the processing body (P-body), where it is degraded or stored. The
contribution of each mechanism remains debated [53–56]. By regulat-
ing the expression of several target genes, each miR has the potential
to imprint a strong molecular signature. Furthermore, individual
mRNAs can be targeted bymultiple miRs, allowing for high combinato-
rial complexity and regulatory potential. In fact, miRs are predicted to
exert ﬁne-tuning of posttranscriptional regulation to N60% of mamma-
lian protein-coding mRNAs [57].ation Preparation time Follow-up time Patency Reference
nous vein graft 2 months 3 years 27/33 [151]
nary artery 2.5 months 7 months 3/3 [152]
PC Hours 7 years 25/25 [42]
ovenous us shunt 4 months 13 months 6/6 [41]
hepatic portal vein 1 month 1 year 1/1 [40]
l cavopulmonary connection; VSMCs: vascular smooth muscle cells.
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targeting could help to: 1) enhance the quantity and/or quality of cells
available for cell-based therapeutic angiogenesis and/or for VTE; 2)
promote stem cell differentiation to vascular cells to be seeded in the
scaffolds (see Fig. 1); 3) improve the function of the cells in the vascular
scaffold acting at different levels (see Table 2); and 4) correct anti-
angiogenic molecular defect and/or amplify endogenous proangiogenic
pathways directly in the ischemic tissue, thus promoting therapeutic
angiogenesis leading to blood ﬂow recovery. To reach these goals, a
good understanding of the impact of different miRs that modulate
vascular and stem cell biology is essential. Here we focus on how miRs
could be utilised to manipulate EC and mural cells in order to enhance
the outcome in VTE and to therapeutically induce angiogenesis in
patients with either IHD or PAD leading to CLI.
5.2. MicroRNAs that regulate endothelial cell function and angiogenesis
ECs form the inner layer of any blood vessel ensuring vascular
homeostasis; and have an essential role during developmental and
post-natal angiogenesis. Pre- or post-implant vascularization of TE
structures is essential for their engraftment. Moreover pre- or post-
implant endothelization of the VTE lumen is mandatory to enable the
grafted vascular conduit to mimic healthy blood vessels, where the
endothelium contributes to regulation of vascular dilatation with no in-
timal hyperplasia, calciﬁcation, atherosclerosis and thrombosis. In VTE,
EC growth and maintenance have been traditionally promoted using
GFs such as VEGF and TGFβ [58]. After recent studies reporting on num-
ber of miRs as key in vitro and in vivo regulators of vascular EC function,
proliferation and growth, it is sensible to suggest that ad hoc miR
targeting could be applied alone or in combination with GFs to improve
endothelial coverage and endothelial function in VTE. Initial evidence
for a functional role of miRs in vascular ECs was provided by the
observation thatmice carrying aDicer hypomorphic allele die prenatally
with severely disrupted blood vessel formation accompanied with
retarded expression of early endothelial markers [10]. Moreover, early
studies showed that silencing of either Dicer or Drosha impaired
the proangiogenic capacities of ECs, which could be restored by co-
transfection of mimics of members of the miR-17–92 cluster, one of
the most important vascular miR systems. [59–61] In early studies,
Poliseno et al. performed a large scale analysis of miRs in humanEndothelial cells Smooth muscle cells
Stem cells
miR-99b 
miR-181a/b 
miR-200c 
miR-150 
Stem cells 
miR-143/145 
miR-10 
miR-1 
Fig. 1.microRNAs reported to be enhanced on vascular differentiation of stem/progenitor
cells. MiR-99b, -181a/b, -200c and -150 induce differentiation of human ESC to endothelial
cells. miR-1 and -145 induce smooth muscle cell differentiation from human cardiomyocyte
progenitor cells and human ESC respectively. miR-10 induces mouse ESC differentiation to
smooth muscle cells.umbilical cord ECs and showed that 15 highly expressed miRs have
the receptors of angiogenic GFs as their putative direct targets [62]. It
is now well established that several miRs are important for endothelial
development, physiology and for angiogenesis [62–65]. Therefore, we
speculate that during VTE it would be possible to intervene therapeuti-
cally by inhibiting pathogenic or anti-angiogenic miRs as well as by
overexpressingmiRs that elicit positive effects on the endothelium. Sev-
eralmiRs have been described to be expressed and functionally relevant
in ECs. For a general overview, the readers can refer to previous review
articles [24, 66–70]. Here, we will discuss miRs whose manipulation
might be beneﬁcial to maintain an integral and functional endothelium
in VTE and thosemiR targeting for inducing therapeutic angiogenesis in
IHD and CLI.
One of the major hurdles in using fully differentiated ECs in VTE
is that after about 70 cell cycles, ECs can no longer divide thereby
potentially affecting the functionality of the construct [71]. The limited
replicative capacity of adult vascular cells is due in part to the progres-
sive shortening of the telomeres over time. Ectopic expression of
telomerase in somatic cells using a retroviral vector has been shown
to reverse the telomere shortening; nonetheless this approach raises
safety concerns since random incorporation of retroviral vectors may
activate oncogenes [72]. Recent studies have shown that miRs play a
vital role in controlling EC senescence and proliferation. In details,
miR-217 overexpressionwas shown to promote endothelial senescence
and miR-217 inhibition by transfecting with antagomir-217 ultimately
reduced senescence and increased angiogenic activity in “old ECs”
[73]. Moreover, miR-34a has been shown to promote senescence in
different cells, including cardiovascular cells [74]. miR-34a over-
expression signiﬁcantly increased EC senescence and impeded angio-
genesis [75]. By contrast, miR-34 inhibition by seed-targeting 8-mer
locked nucleic acid (LNA)-modiﬁed antimiR (LNA-antimiR-34) promoted
angiogenesis in mouse ischemic models [76, 77]. Thus, we speculate that
the inhibition of miR-217 or miR-34a as well as other miRs which could
be discovered to induce EC senescence could be useful to obtain a healthy
endothelial layer in VTE.
An alternative approach to seeding ECs directly onto scaffold would
be to recruit progenitor cells from the circulation. The immature cells
would eventually differentiate into ECs on the lumen of the scaffold.
This in situ VTE approach takes advantage of the regeneration potential
of the host cells to regenerate a blood vessel in situ following vessel
implantation. The advantage of this approach (which is treated in
more details in the 5.4 section) would be that the graft preparation
would need less extensive in vitro culture and manipulation).
Moreover, for VTE, miRs that are expressed in ECs and regulated by
ﬂow are particularly relevant. A number of ﬂow sensitive miRs have
been identiﬁed and named as mechano-miRs [69]. They include miR-
10a, -19a, -23b, miR-21, -663, -92a (and possibly other members of the
miR-17-92 cluster), miR-143/145, -101, -126, -712, -205, and miR-155
(reviewed in [69]). The key signalling pathways that are targeted by
these mechano-miRs include cell cycle, inﬂammation, apoptosis, and
nitric oxide signalling [69]. Many of these miRs were initially identiﬁed
as ﬂow sensitive in vitro and were later found to play a critical role in
endothelial (dys)function, inﬂammation and atherosclerosis in vivo
(reviewed in [69]). For these reasons, it might be worth to test whether
ex-vivomanipulation of these individualmiRs or their combination could
improve the performance of the engineered vascular conduit preventing
its stenosis and thrombosis once this is implanted in patients.
Of importance for the therapeutic angiogenesis part of this article,
the expression of miRs is regulated by hypoxia and ischemia [78–83]
and miRs shape post-ischaemic responses, including the vascular
regenerative capacity of transplanted cells with proangiogenic capacity
[11, 78] (Fig. 2). Based on the relationship between miRs and other
angiogenesis regulators, we propose to classify angiogenesis-related
miRs into two groups: 1) miRs that directly target genes regulating
angiogenesis 2) miRs that can be modulated by pro-angiogenic or
anti-angiogenic stimuli. The ﬁrst group includes the so called ‘angio-
Table 2
Possible miR targets for vascular tissue engineering dedicated to patients.
miR Target Targeted
cells
Modulation Modulation
strategy/factor
Outcome Ref
17–92 Jak1 EC Downregulation Antagomir Increased angiogenesis [153]
217 SIRT1 EC Downregulation Antagomir Reduced senescence and increased angiogenesis [73]
34 Vinculi, Notch1, semaphorin 4B EC Downregulation LNA Increased angiogenesis [76]
143/145 Klf-2 EC, VSMC Upregulation Laminar shear stress Inhibit VSMC dedifferentiation [109]
19a Cyclin D1 EC Upregulation Laminar shear stress Induce endothelial senescence [154]
155 MYLK EC Upregulation Laminar shear stress Inhibit EC proliferation and migration [155]
92a Klf-2/4 EC Upregulation Low shear stress Induce endothelial inﬂammation [156]
663 Klf-4 EC Upregulation Oscillatory shear stress Induce endothelial inﬂammation [157]
126-5p Dlk-1 EC Downregulation Disturbed ﬂow and low
shear stress
Inhibit EC proliferation [158]
10a MAP3K7 EC Downregulation Disturbed ﬂow and low
shear stress
Induce EC inﬂammation, hyperpermeability [159]
205/712 TIMP3 VSMC Upregulation Disturbed ﬂow Induce VSMC migration [160]
126 SPRED-1, PIK3R2 EC Upregulation Blood ﬂow Pro-angiogenic [161]
17-5p TIMP1 HUVEC Upregulation VEGF Pro-angiogenic [162]
18a Tsp1 HUVEC Upregulation VEGF Pro-angiogenic [162]
31 UD HUVEC Upregulation VEGF Pro-angiogenic [162]
155 ATR1 EC Upregulation VEGF Pro-angiogenic [162]
210 Ephrin A3 EC Upregulation Hypoxia Pro-angiogenic [65]
424 CUL2 EC Upregulation Hypoxia Pro-angiogenic [85]
200c Zeb1 EC Upregulation ROS Induce EC death and senescence [86]
217 SirT1 EC Downregulation Antagomir Reduce senescence in ageing EC [73]
34 SirT1 EC Downregulation Antagomir Reduce senescence in ageing EC [88]
503 CCNE1, cdc25A EC Downregulation Adenovirus-mediated
miR-503 decoy delivery
Enhance post LI vascular repair [90]
101 EZH2 HUVEC Downregulation Antagomir Increased EC tube formation and migration [91]
132 RasGTPase activating protein,
methyl-CpG-binding protein 2
Pericytes Downregulation Antagomir Decreased pericyte capacity to improve contractility,
reparative angiogenesis
[78]
143/145 Elk-1, Klf-4 VSMC Downregulation Antagomir Induction of synthetic phenotype [106]
221/222 p27 (Kip1), p57 (Kip2) VSMC Downregulation 2′-O-methyl modiﬁed
antagomir
Induction of contractile phenotype [110]
21 Pten, Bcl2 VSMC Upregulation TGF-b and BMP signalling Induction of contractile phenotype [114]
21 PDCD4, Sprouty-2, PPAR VSMC Upregulation Hypoxia Induction of synthetic phenotype [114]
24 Trb3 VSMC Upregulation PDGF β Induction of synthetic phenotype [112]
34a SIRT1 VSMC Upregulation miR-34a mimic Induction of cell cycle arrest [116]
29a VDAC1/2 VSMC,
ﬁbroblasts
Downregulation miR-29a inhibitor Induce elastin production [115]
99b, 181a, 181b Prox1 hESC Upregulation Lentiviral Enhance efﬁciency of EC lineage commitment,
improved post ischemic blood ﬂow recovery
[11]
200c, 150 Zeb1 hESC Upregulation Precursor miR-200c, 150 Induce differentiation to EC [122]
145 KLF-4/5 hESC Upregulation Precursor miR-145 Induce differentiation to VSMC [126]
1 KLF-4 mESC Upregulation miR-1 mimic Induce differentiation to VSMC [128]
10a histone deacetylase 4 mESC Downregulation Inhibitor Reduction in VSMC differentiation [130]
15a/16 VEGF-A, AKT-3 EPC Downregulation Antagomir Improved survival and migratory capacity [83]
150 CXCR4 MNC Downregulation Lentiviral Increased MNC migration from bone marrow to
peripheral blood
[133]
ECs: endothelial cells, VSMCs: vascular smooth muscle cells, HUVECs: human umbilical vein endothelial cells, hESCs: human embryonic stem cells, mESCs: mouse embryonic stem cells,
EPCs: endothelial progenitor cells, MNC: mononuclear cell, UD: undeﬁned.
Pr
o
-a
n
gi
og
en
ic
miR-17-5p
miR-18a
miR-20a
miR-210
miR-31
A
nt
i-a
ng
io
ge
n
ic miR-34
miR-101
miR-503
miR-200c
miR-217
Angiogenic stimuli:
Hypoxia/VEGF
Anti-Angiogenic stimuli:
ROS/Senescence/
Diabetes
miR-155
miR-424
Fig. 2. Angiogenesis regulatory miRs. MiRs that respond to pro-angiogenic stimuli or anti-
angiogenic stimuli are enlisted.
83M. Caputo et al. / Advanced Drug Delivery Reviews 88 (2015) 78–91miRs’, encompassingmiR-126, miR-221/222 and the miR-17-92 cluster
[66]. The second group of miRs can be controlled by either single
molecules or more complex environmental conditions that promote
or impair the angiogenesis process. For example, the Sessa laboratory
found that VEGF-A induces time-dependent expression of miR17-5p,
-31, -155, -18a, -20a in HUVECs [84]. Hypoxia was found to enhance
the expression of two pro-angiogenic miRs, miR-210 [65] and -424
[85] in ECs. On the other hand, a number of miRs are regulated by
anti-angiogenic signals such as ROS, senescence, high glucose etc.
Study conducted by Magenta et al. showed that the negative effects of
ROS on EC survival was due to the upregulation of miR-200c [86].
MiR-217 [87] and miR-34 [88] are reported to be upregulated in ageing
ECs. Inhibition of these two miRs with speciﬁc antagomirs ultimately
reduced senescence and increased angiogenic activity possibly via an
increase in SIRT1 activity [73, 88]. The most studied miRs regulated by
pro/anti-angiogenic stimuli are listed in Fig. 2. We have recently
reviewed the topic of miRs in vascular context and we refer the readers
to this previous publication [24].
84 M. Caputo et al. / Advanced Drug Delivery Reviews 88 (2015) 78–91Finally, diabetes mellitus has a severe damaging effect on the ECs in
both large and small vessels [21, 89]. Part of these actions ismediated by
miRs, includingmiR-503 [90] andmiR-101 [91]. In two separate studies,
we have reported increasedmiR-503 and-101 expression in EC exposed
to type 1 diabetes mellitus and gestational diabetes, respectively [90,
91]. Moreover, forced overexpression of miR-503 and miR-101 in
cultured ECs resulted in impaired cell migration, proliferation and net-
work formation [90, 91]. When considering use of VTE and therapeutic
angiogenesis in diabetic patients, it is sensible to consider if an additional
pool of miRs should be targeted to improve the clinical outcome.
5.3. MicroRNAs that regulate pericyte function
As aforementioned, pericytes play important role in providing
stability and nurturing signals to microvessels and maintaining proper
capillary function, including in the vasa vasorum [92]. The use of
pericytes in vascular regenerativemedicine approaches has been limited
by the lack of knowledge in the biology of these cells in comparison to
the more widely studied ECs and VSMCs [93]. Moreover, there have
been difﬁculties in isolating and expanding pericytes from human tissue
samples. To harness the full potential of pericytes for VTE, themiR proﬁle
of these cells should bemore carefully investigated. Murinemicrovascu-
lar pericytes have been shown to expressmiR-145 [94]. Moreover, amiR
array performed on rat cortical pericytes has shownexpression of several
miRs and their regulation by hypoxia [95]. As described below, we were
the ﬁrst to identify miR-mediated actions in human pericytes [78].
At amore advanced stage of VTE optimisation, the engineered vessel
should contain vasa vasorum (which include pericytes) to support its
perfusion. Currently, the vascular architecture has not been engineered
so precisely. However, the feasibility of using pericytes in VTE was
shown in a recent study which used bi-layered elastomeric poly
(ester-urethane) urea scaffolds [96]. Pericytes (3 × 106 cells) were de-
rived from human skeletal muscles and bulk seeded onto the scaffolds
using a rotational vacuum seeding device in less than 2 min [96]. The
seeded scaffolds were cultured in spinner ﬂasks for 2 days and then im-
planted to immunocompetent Lewis rats as aortic interposition grafts
for 8 weeks [96]. Pericytes successfully populated the porous layer of
the scaffolds evenly after the dynamic culture and post implantation
showed a signiﬁcant higher patency rate than the unseeded control
(100% vs 38%) [96]. In this study, the miR proﬁle in the employed
human cells was not analysed.
Recently, our group have succeeded in isolating and expanding a
clonogenic population of pericyte progenitors (the “Bristol pericytes”)
from saphenous vein left overs of patients undergoing coronary artery
bypass graft surgery [97]. The Bristol pericytes have shown pro-
angiogenic and anti-ﬁbrinogenesis capacities when transplanted in
mouse models of CLI [97] and IHD [78]. We have characterized the
proangiogenic response induced by the Bristol pericytes in vitro using
a co-culture system with ECs. Pericytes induced a paracrine activation
of angiogenesis response by ECs through the release of miR-132 [78].
This response was augmented under hypoxic conditions, suggesting
that this might be highly relevant in the proangiogenic actions induced
by the Bristol pericytes once transplanted in the ischemic heart or limbs.
In line with this hypothesis, complete ex-vivo inhibition of miR-132 ex-
pressionwith an antagomir in the pericytes before their transplantation
in mice with IHD compromised the regenerative properties of these
cells [78]. An added advantage of the Bristol pericytes is their low im-
munogenic proﬁle and resistance to hypoxia/starvation [78]. MiR-132
additionally controls pericyte proliferation and survival in vitro [78].
From the above, overexpressing miR-132 levels in pericytes would
improve their ability for reparative vascularisation. However, few miR
overexpression strategies have been developed due to the caveat that
miRmimic oligos are unstable, have transient effects andwould require
multiple administrations [24]. This could be overcome by using vessel
targeted nanoparticles to systemically deliver the miR mimics directly
to the site of post-ischemic angiogenesis and also in tissue engineeredconstructs. Anand et al. recently used vessel targeted nanoparticles to
deliver antagomir-132 to block angiogenesis in a mouse tumour
model [63]. A similar delivery approaches might be utilised for deliver-
ing miR-132 mimics for enhancing pericyte functions. Importantly, it
was also observed that the expression levels of miR-132 in the Bristol
pericytes can be upregulated up to 3-fold times by hypoxia or by
stimulation with VEGF-B [78]. Hence it would be important to consider
addition of factors such as VEGF-B and/or hypoxia to enhance miR-132
levels in the pericytes used for vascular regenerative approaches. We
are currently moving our work with pericytes derived from adult and
paediatric cardiac surgeries to TE approaches (Caputo, Angelini and
Madeddu, unpublished data 2014 and 2015).
Ischemic diseases are shown to impair the pericyte recruitment to
capillaries [98]. Hence supply of pericytes from exogenous sources ap-
pears therapeutically beneﬁcial. An alternative to cell transplantation
would be to target the pericytes resident in the ischemic heart and
limb muscles with miRs that are able to stimulate their survival and
function; as well as to inhibit miRs that have negative effects on these
cells. To initiate this research, full genome miR proﬁling of human miR
pericytes in IHD and CLI is fundamental; and this should be followed
by expressional and functional validation efforts. In consideration of
the fact that pericytes are severely compromised by diabetes [99, 100],
the screening and validation studies should be separately conducted
on samples from diabetic and non-diabetic patients.
Collectively, these studies suggest the promises of human pericyte
populations in VTE and therapeutic angiogenesis and stimulate more
research on these cells and their therapeutic use. Finally, the possibility
to empower pericytes through miR targeting is emerging.
5.4. MicroRNAs that regulate vascular smooth muscle cell function
It is now well established that the smooth muscle layer of the blood
vessel contributes an important role in ensuring vessel homeostasis and
functions. In addition to their vascular physiological roles, VSMCs are
also important players in the vascular remodelling processes observed
under pathological conditions [101, 102]. VSMCs are one of the most
plastic cells in the body being able to switch between a differentiated
(contractile) state and a proliferative (synthetic) phenotype depending
on the signals received [101]. Following an injury, VSMCs dedifferenti-
ate to promote repair of vessels and once the injury is resolved,
“healthy” VSMCs should return to contractile phenotype [101].
Although this modulation is critical for vascular repair, this plasticity
sometimes contributes to the development and progression of vascular
pathologies. One of the limitations of current VTE prosthesis is stenosis
caused by excessive proliferation of VSMC, termed as intimal hyperpla-
sia [103]. Thus, themodulation of VSMC between quiescent ‘contractile’
phenotype and proliferative ‘synthetic’ phenotype is crucial when
designing VTE approaches.
VSMC function was recently found to be heavily inﬂuenced by miRs
[37]. While some of the miRs promote VSMC proliferation, others
stimulate differentiation. MiR-143 and -145 are among the most highly
expressed miRs in VSMC and they are known as critical regulators in
VSMC differentiation. Studies conducted in miR-143/-145-deﬁcient
mice revealed that VSMC requires these two miRs to switch from its
contractile to synthetic function [104, 105]. The mechanism by which
miR-145 regulate VSMC phenotype was deﬁned by the elegant set of
studies by Cordes et al. which showed that the miR-143/-145 cluster
targets a network of transcription factors that promote differentiation
and repress proliferation in VSMC [106]. The signiﬁcance of miR-143/-
145 in human vascular diseases is suggested by the observation that
miR-143/-145 levels are decreased in patients with aortic aneurysm
and CAD [107, 108]. A recent study revealed that extracellular vesicles
(EVs) derived from KLF2-expressing ECs promote the contractile
phenotype of co-cultured VSMCs by downregulating target genes of
miR-143/145 [109]. The concept of cell-to-cell communication by
transfer of miRs is discussed in detail toward the end of this review.
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These miRs were found to be expressed in normal arteries and signiﬁ-
cantly up-regulated after balloon angioplasty [110]. Furthermore,
inhibition of miR-221/222 in vivo signiﬁcantly reduced neointimal
formation, demonstrating for the ﬁrst time the potential of VSMC
miRs as therapeutic targets for treatment of vascular disease [111].
MiR-221/-222 were downregulated in the balloon-injured rat carotid
artery via 2′O-Methyl-modiﬁed antagomirs [111]. The miR inhibitor
was pre-loaded into F-127 pluronic gel and applied locally to the adven-
titia around injured artery segments [111]. This method of delivery
reduced any potential systemic side effects. A similar approach could be
considered for improving VTE before or immediately after implantation.
Collectively these studies highlight the important role played by
miRs in maintaining the phenotype of VSMC. Direct and/or indirect
modulation of these miRs would be beneﬁcial in maintaining the
“optimal” phenotype of VSMC for VTE. Along with miRs, GFs and
environmental cues also play important roles in VSMC phenotypemod-
ulation. For example, studies conducted in human primary pulmonary
VSMCs showed that PDGF signalling is a potent inducer of the synthetic
phenotype and propose that it acts via induction of miR-24 [112]. miR-
221 is also reported as a modulator of the phenotypic change of human
pulmonary VSMCs in response to PDGF signalling [113]. Thus, identify-
ing the underlying pathways and cytokines involved inmiRmodulation
should allow us to use them alongside miR targeting in VTE. However
one must be careful about the side effects, since the same miR may
have different responses under different conditions, and hence miR
therapeutics can elicit off-target effects. For example, TGF-β and BMP
signalling was reported to induce a contractile VSMC phenotype by
increasing miR-21 [114]. However, hypoxia induced upregulation of
miR-21 was found to induce the synthetic phenotype [114]. Hence
more in-depth studies in this direction are required to understand the
best miRs and/or GFs combinations that would be beneﬁcial for VTE.
Similar to ECs, VSMCs can become senescent, which is detrimental
for the VTE process. The limited replicative capacity of adult vascular
cells is due in part to the progressive shortening of the telomeres with
donor age [115]. This is particularly relevant when planning autologous
VTE approaches in adult patient population, while it can be a minor
issue for paediatric CHD surgical cases. A recent study has shown that
miR-34a induces VSMC senescence by SIRT1 downregulation and
promotes the expression of age-associated pro-inﬂammatory secretory
factors leading to arterial dysfunction [116]. Increased miR-34a as well
as decreased SIRT1 expression was also observed in replicative-
senescent human aortic VSMC. miR-34a overexpression by transfecting
with miR-34a mimic in proliferative human aortic smooth muscle cells
induced cell cycle arrest [116]. miR-34a ectopic expression signiﬁcantly
increased the percentage of VSMCs in G0–G1 phase at 24 h post-
transfection when compared with negative control [116]. From the
above and the work on miR-34 in ECs described in above Section 5.2,
we can suggest miR-34a inhibition to be worth being tested in VTE
protocols.
5.5. MicroRNAs that modulate extracellular matrix production
In an effort to produce ‘off-the-shelf’ vascular grafts with an ade-
quate ECM, Dahl et al. seeded human VSMC onto PGA scaffolds in vitro
that were later decellularised and stored till the time of patient need
[117]. These acellular human-based vascular grafts could be implanted
directly into the patient or could be seeded with autologous ECs for
small diameter vessels. Though the patientwaiting time could be signif-
icantly reduced with this approach, the donor-to donor variation in the
ability of VSMC to generate ECM in vitro remains a major challenge.
VSMCs are the major producers of ECM. The successful generation of
tissue engineered blood vessels in vitro has been estimated to require
almost 8–24 weeks of cell culture time to generate adequate ECM
necessary for arterial grafts [39, 41]. The mechanical strength of the
vessel is largely derived from the ECM components such as collagenand elastin. Older cells deposit less ECM than younger cells due to
downregulation of ECM production and elastogenesis [118]. This leads
to the generation of vessel grafts with poor mechanical properties,
such as burst pressure and suture retention [118]. A recent study has
shown that inhibition of miR-29a can dramatically increase elastin
expression in human cells and thatmiR-29 inhibition upregulates elastin
levels in cells from patients with elastin haploinsufﬁciencies and in
bioengineered human blood vessels [115]. In this study, polyglycolicacid
(PGA) scaffolds were seededwith early passaged human VSMCs and the
vessels were grown in a bioreactor for 6 weeks in the absence or pres-
ence of miR-29a inhibitor. Complete miR-29a inhibition increased the
appearance of elastin “islands”, thereby increasing the distensibility of
the bioengineered vessels at low pressures [115]. Thus, antagonizing
the actions of miR-29 may promote increased elastin levels during
conditions of enhanced elastinolysis or deﬁciencies.
5.6. MicroRNA targeting for improving the process of stem cell differentiation
to vascular cells and the functional capacities of vascular progenitor cells
The re-population of a decellularised matrix with a patient's own
stem cells can potentially create a living structure with subsequent
long-term preservation of mechanical and biological properties. A
number of studies have focused on techniques to promote vascular
differentiation from stem cells. With the discovery of miRs, a new
route to enhance stem cell differentiation to vascular lineages has pre-
sented itself. The possibility to achieve efﬁcient generation of unlimited
supplies of vascular cells and vascular progenitor cells from stem cells
would be highly beneﬁcial for VTE and therapeutic angiogenesis. Our
group and others have established in vitro protocols for human embry-
onic stem cells (ESCs) differentiation to endothelial progenitor cells and
ECs [119–121]. Microarray proﬁling of miR expression at subsequent
stages of differentiation identiﬁed miR-99b, -181a and -181b as key
miRs involved in the process [119]. Lentiviral mediated overexpression
of these miRs in ESCs enhanced the efﬁciency of EC lineage commit-
ment. Moreover the ESC-derived ECs showed improved capacity to
promote post-ischemic blood recovery in immunocompromised mice
with experimentally induced limb ischemia [119]. The ﬁndings from
the study by Luo et al. suggest that as human ES cells differentiate to
the EC lineage, miR-200c and miR-150 are upregulated resulting in EC
differentiation [122]. The study by using in vivo inhibition of the men-
tioned miRs (using antagomirs), also showed that miR-200c and -150
played an important role in chick embryonic blood vessel formation
[122].
Another study showed miR-126 to be abundantly expressed in
mesodermal progenitor cells derived from stem cells and to regulate
mature EC function. However, lack of an embryonic lethal phenotype
with genetic miR-126 deletion suggests that miR-126 does not com-
mand early endothelial lineage commitment and it becomes relevant
later during vascular differentiation [123]. Similarly the miR-17–92
cluster has been reported to be expressionally regulated during EC
differentiation from pluripotent stem cells, but it was not shown to
functionally impact on the process [124].
Dar et al. recently showed successful generation of pericytes from
human ESCs and induced puripotent stem cells (iPSCs) [125]. Co-
implantation of iPSC-derived ECs and pericytes into immunodeﬁcient
mice resulted in signiﬁcant vascular and muscle regeneration [125].
Whether miRs contribute into stem cell differentiation into pericytes
has not been clariﬁed, yet. Therefore further studies are required.
MiR-143 and -145 are verywell characterized in the vasculature and
are positioned as a central target of multiple growth factor signalling
pathways inﬂuencing VSMC differentiation and maintenance. A recent
report has shown that overexpression of miR-145 can regulate the
fate and phenotype of human ESC-derived pre-VSMCs as they fully
differentiated to VSMCs [126]. Overexpression of miR-145 was induced
by the transfection of 100 nM precursor miR-145 (premiR-145), which
resulted in a greater than 3000 fold increase in miR-145 level in human
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of KLF4 (one of the pluripotency factors present in the “Yamanaka
cocktail” used to reprogramme differentiated cells to pluripotency)
[127]. It also upregulated the expression of smooth muscle markers,
and changed the cell morphology into a differentiated spindle-like
shape phenotype. Furthermore, introduction of miR-145 inhibited the
proliferation of the ESC-pre-VSMC and increased their carbachol-
stimulated contraction. In contrast, downregulation ofmiR-145 (knock-
down by 100 nMmiR-145 inhibitor— “antimiR-145”) in ES-pre-VSMCs
upregulated KLF-4 and -5 expression and suppressed the expression of
VSMCmarkers [126]. Collectively, these studies show that miR-145 can
regulate the fate and phenotype of human ESC–VSMCs as they become
fully differentiated VSMCs. Hence, miR-145 could be used to modulate
stem cell differentiation to VSMCs for VTE. However, it should be
noted that animals with miR-145 knock out are viable through adult-
hood, suggesting the role of additional miRs in the process of VSMC
differentiation.
MiR-1 expression is reported to be increased during differentiation
of mouse ESCs to VSMCs [128]. KLF4 was found to be a common target
for both miR-143/145 and miR-1 [128]. The study showed that when
miR-1 is overexpressed by transient transfection of miR mimic, KLF4 is
repressed and VSMC differentiation is promoted [128]. MiR-1 is also re-
ported to mediate the vascular differentiation of human cardiomyocyte
progenitor cells, a cell population which can be derived from human
atrial and ventricular tissue obtained as surgical waste and that can be
differentiated into both VSMCs and ECs [129]. Another miR reported
to be involved in VSMC differentiation is miR-10a [130]. The expression
of miR-10 was found to be increased during mouse ESC differentiation
to VSMCs [130]. Inhibition of miR-10 (transient knock down using
miR inhibitor) resulted in a substantial reduction in VSMC differentia-
tion [130]. Collectively, these studies provide the ﬁrst evidence that
miRs play a major role in directing and regulating stem cell differentia-
tion into vascular cell lineages and hence that miR targetingmay repre-
sent a valuable tool to improve the availability of vascular cells to be
used in TE. Even if this approach has not yet been explored in VTE, a
proof of concept was recently provided in bone tissue engineering.
Mariners and team transfected human mesenchymal stem cells with
mimics of miR-148-b and inhibitors of miR-489, two miRs that were
linked to osteogenesis [131]. The investigators seeded these cells into
osteoinductive scaffolds, which resulted in better ECM deposition and
bone formation. This work on bone tissue engineering can potentially
be used as a template for using miR modulation strategies for vessel
regeneration.
MiR targeting could be additionally used to empower patient-
derived autologous progenitor cells and circulating proangiogenic cells
to be employed both in VTE and for direct transplantation into ischemic
tissue. Moreover, we suggest that miR targeting approaches might
improve the release of endothelial chemoattractant messengers from
VSMCs seeded in scaffolds, which should facilitate the endothelization
of the graft after its implantation by promoting EC migration from the
bordering native vasculature as well as by recruiting blood circulating
endothelial progenitor cells. Bonemarrow (BM)-derived proangiogenic
cells (PACs), which were previously known as early endothelial progen-
itor cells (EPCs), have been implicated in both native and therapeutically
guided angiogenesis [132]. Our group have recently shown thatmiR-15a
and miR-16 profoundly inhibit the migratory potential of PACs isolated
from patients with CLI [83]. Ex vivo manipulation of PACs with anti-
miR-15a/16 improved survival and migratory capacity of these cells
and increased post-ischemic recovery of mice with limb ischemia [83].
Moreover, Tano et al. showed that the number of circulatingmononucle-
ar cells (MNCs) as well as of CXCR4 positive MNCs were increased by
acute IHD (an heart attack) in patients and identiﬁed miR-150 as a key
regulator for mobilizing these cells from the BM by targeting CXCR4
[133]. Knock down of miR-150 by transfection with its inhibitor in
MNCs resulted in enhanced migration capacity. Moreover, lenti-virus
mediated knock down of miR-150 signiﬁcantly increased CXCR4expression in MNCs and increased MNC mobilization from BM to PB
when transplanted into the BM of wild type mice [133]. This indicates
that miR-150 is associated with stem cell mobilization by targeting
CXCR4. Another study showed that microvesicle based exogenous miR-
150 delivery to human microvascular EC enhanced their migration
ability in vitro [134]. Collectively these studies show that miRs inﬂuence
recruitment of progenitor cells and could be used as a therapeutic tool for
effective host cell mobilization to the lumen of the scaffold in VTE.
6. MicroRNA therapeutics
As discussed earlier in this review, miRs have an essential role in
vascular biology and pathology as well as in stem cells differentiation
into vascular cells. To fully utilise the power of these master regulators
in VTE, there are several aspects that needs to be answered effectively.
Firstly, the choice of miR modulation strategies needed to give the
desired effect in VTE should be carefully considered. Secondly, how
these strategies would be delivered/used in a VTE perspective. We will
look into the approaches for therapeutic miR delivery strategies in the
following section.
Studies conducted over the last decade clearly show that miRs are
involved in almost all types of cellular processes, making them an at-
tractive therapeutic target that could be used in VTE. The clinical studies
conducted so far using GFs to enhance or modulate the cell source in
VTE has met with limited success. The limitations of current techniques
could be effectively overcome by the adequate use of “miR drugs”.
Strategies for miR-based therapies are based on either the restoration
of suppressed genes by inhibiting the speciﬁc miR and or the delivery/
overexpression of the miRs that suppress those target genes that have
a desired effect on the cell source or signal used in VTE. However, care
must be taken when targeting miRs that have multiple targets to
avoid unexpected side effects.MiRs are differently involved in themain-
tenance of a variety of cell types. Therefore it cannot be excluded that
the same miR can be advantageous to the cell population we want to
target, but have negative side effects on other cells or tissues. Hence, it
becomes evident that a ﬁnely tuned “miR drug” delivery is needed to
avoid potential harmful side effects. For example, the aforementioned
miR-34a involved in vascular cell senescence [75, 116], is one of the
most characterized tumour suppressor miRs in a variety of tumours
[135]. Based on these considerations, chemical modiﬁcations aimed to
improve the biological stability of selected miRs could be successfully
combined with targeted active delivery approaches, allowing easier
clinical translation.
6.1. “MicroRNA drugs” delivery during the vascular tissue engineering
process
Selecting the right miR drug delivery strategy for VTE is crucial in
determining the success of the construct. The major challenges in
delivering plasmid and oligonucleotide-based miR therapies are nucle-
ase degradation, limited cell membrane permeability, and generally
transient activity. Delivery strategies must be selected based on the
class of miR therapy chosen and also on the target tissue. For instance,
for localized applications, such as vascularising a tissue engineered
construct that can be easily accessed, a direct tissue injection can be
optimal. Controlled release of miRs could be achieved by using biode-
gradable scaffolds that can simultaneously act as a tissue template and
as a source of sustained miR release [136]. This would also allow more
spatiotemporal control over miR activity. It would be also ideal to do
material surface immobilisation of “miR drugs” to enhance local deliv-
ery and to minimize off-target effects. In cases where the tissue is not
easily accessible, systemic delivery approaches should be considered
[90]. The delivery of synthetic oligonucleotides in NPs or microparticles
could be used to prevent their rapid degradation by cellular and
serum nucleases and could prevent them from crossing through cell
membranes. This could signiﬁcantly reduce off target effects and ensure
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NPs to deliver miRs able tomodulate angiogenesis. Anand et al. used ves-
sel targeted NPs to deliver miR-132 [63]. The study used an integrin
αvβ3-targeted nanoparticle that can deliver nucleic acids or drugs to
the tumour neovasculature for selective delivery of anti-miR-132 to the
cancer endothelium in mice. Systemic administration of anti-miR-132
NPs blocked cancer angiogenesis [63]. The NPs were composed of
distearoylphosphatidylcholine (DSPC), cholesterol, dioleoylphosphatidyl-
ethanolamine (DOPE), distearoylphosphatidylethanolamine (DSPE)-
mPEG2000, and DSPE-cyclic RGDfK. Mice were treated with 50 μg
of scrambled anti-miRNA or anti-miR-132-NPs intravenously every
2 days starting from day 12. Injection of a single dose of anti-miR-132
in the RGD NPs decreased tumour size transiently with a half-life of
biological efﬁcacy of 2 days [63]. These NPs can be used to deliver inhib-
itor of miRs that impair angiogenesis and the VTE process. They could
also be employed to deliver mimics of miRs that are beneﬁcial in this
context. In summary, this study suggests a good approach for targeted
NP-based miR delivery that could be utilised with VTE.
Another approach would be to ex-vivo deliver miR therapy to cells
to modulate cell differentiation or survival as required for the VTE
construct. In a recent report Devalliere et al. report on a new approach
for enhanced EC transplantation using targeted NPs transfection to
deliver proangiogenicmiR-132 to cultured ECs before their transplanta-
tion, thereby sensitizing cells to the effects of endogenous GFs [137].
Transfection of ECs with miR-132 enhanced GF-induced proliferation
andmigration in 2D culture [137]. However,while the effects of conven-
tional transfectionwere short-lived, nanoparticle transfection produced
protein knockdown and biological effects that were signiﬁcantly longer
in duration (≥6 days) [137]. Transfection of ECs with miR-132 NPs
resulted in a 2-fold increase in the number of microvessels per square
millimeter compared to lipid after transplantation into immunodeﬁ-
cient mice and led to a higher number of mural cell-invested vessels
than control transfection [137]. These data suggest that it would be
possible to modulate cell characteristics using miR therapy prior to
their use in VTE.
6.2. MicroRNA delivery via extracellular vesicles
Functionally competent mature miRs are released by cells as conju-
gates with (lipo)proteins [138–140], and/or loaded in extracellular ves-
icles (EVs, exosomes), microparticles and apoptotic bodies [139, 141].
Being inside EVs or conjugated to (lipo)proteins makes extracellular
miRs resistant to degradation [142]. Exosomes and microparticles
(MPs) can transfer biologically active miRs to neighbouring or distant
cells [143]. MiR exchange via exosomes has been shown to modulate
cross-talk between ECs and VSMCs [109] and pericyte with ECs [78]. It
is important to note that the functionality of EVs can be enhanced by
modulating the culture conditions of the producing cells. For example
Lopatina et al. showed that the functionality and number of adipose
MSC-derived EVs can be increased by PDGF stimulation [144]. Another
study by Zhang et al. showed that hypoxic stimulation was required to
obtain functional EVs from BM–MSC [145]. Collectively, these studies
suggest that EVs with the ‘right’ miR or miR combinations can be used
directly to deliver therapeutic miRs to ischemic tissues and at different
steps of the vascular TEprocess. After isolation, EVs can be utilised either
separately or in combinationwith cells or other therapeutics for VTE. Di-
rect injection could be one way of EV delivery into the tissue or circula-
tion. It can be speculated that EVs can be mixed with scaffolds during
preparation or coated onto the scaffolds via chemical linkers, antibodies
or by speciﬁc tags. Use of EVs with biodegradable scaffolds with desired
release proﬁles would allow constant and gradual release of EVs for the
desired effect. A major advantage is that EVs would allow harnessing
the paracrine effects of stem and progenitor cells without having to
administer live (and potentially harmful) stem cell populations. This
would help in easier clinical translationwith regard to safety, regulation
and complexity. However a major challenge that needs to be addressedis how to isolate the required quantity of EV for VTE. The current gold
standard in isolation relies on ultracentrifugation [146]. Although com-
mercial reagents are available for higher yields, these products still
require a lot of optimisation [146]. As an alternative, artiﬁcial EVs can
be engineered with the desired miR cargo to be delivered during VTE
and for therapeutic angiogenesis in IHD and CLI. However, more
research is required in this direction to conﬁrm the feasibility of this ap-
proach. The optimization of EV production would allow one to regulate
the cargo release in response to different physical parameters, including
pH, temperature etc.Moreover, the EV membrane could be engineered
to contain epitopes guiding targeting and delivery into speciﬁc cell
types. From the above, it is apparent that more studies are required to
optimize the angiogenic potential of EVs for their effective use in VTE
and therapeutic angiogenesis.
6.3. Open questions and key challenges in microRNA therapeutics for
vascular tissue engineering
The studies discussed here indicate that miR therapeutics can
have wide applications for VTE supporting the enthusiasm for further
exploration of miRs as novel therapeutic candidates. However numerous
challenges remain in the path toward clinical translation ofmiR therapeu-
tics for VTE. miRs are master regulators targeting several regulatory
networks at the same time. Though this can be highly advantageous in
certain scenarios, the promiscuity of miRs also makes the process of
selecting the right therapeutic miR candidates very challenging. There is
inevitable overlap between key genes controlling pluripotency and differ-
entiation on the one hand cancer initiation and development on the other
[147]. A clear understanding of the complex regulatory networks by bio-
informatics, systems biology and target prediction algorithms is essential.
In most of the animal studies to date, the phenotypic effects of miRmod-
ulation have only been studied in the target tissue of interest, which
might have overlooked off-target effects in additional tissues. Moreover,
the doses used in most pre-clinical studies are unlikely to be clinically
feasible. It would be important to identify optimum dosing regimens to
establish the lowest possible efﬁcacious doses without side effects.
Another important factor that needs to be considered is that tissue re-
pair by VTE is a multi-step process that requires variable levels of miR
modulation depending on the stage of the TE process. Identifying the
miRs that are modulated during biological vascular repair in the body
would be very important for VTE. The best outcomes in miR therapy
for VTE might occur when the temporal provision of miR modulators
are matched to these biological repair processes. MiRmodulation strate-
gies are based on the presumption that relatively modest changes in the
expression of target mRNAs are sufﬁcient to evoke therapeutic beneﬁts.
An interesting study by Mukherji et al. showed that mRNA targets by
miRs display threshold effects such that the mRNA can be efﬁciently
modulated when it is present at relatively low levels compared to miR
[148]. However, when the mRNA is present at a far higher level, the
biological impact of miR becomes diminished since the miRs will not
be able to inhibit it anymore [148]. Hence swamping a system with
miR overexpression or inhibition strategies may be insufﬁcient to
achieve the desired outcome. Another study has shown that transfecting
with miR mimics and miR inhibitors affects the expression of genes
predicted to be under endogenous miR regulation [149]. This effect
was observable at both the mRNA and protein levels [150]. Apart from
controlling the miR levels, precision of targeting is also essential to en-
sure that the modulators are delivered to the targeted cell population.
In summary, for miR therapeutics for VTE needs intelligent target
selection coupled with precise spatiotemporal modulation of miR
targets. This is not a very easy task and requires extensive research.
7. Conclusions and future perspectives
Development of a tissue engineered vessel that is mechanically
robust, biologically functional and clinically compatible is extremely
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factors that need to be considered for VTE. The most successful ap-
proaches so far have utilised vascular cells and the process still require
long times for vessel generation. MiR modulation of cells for use in
VTE is an exciting, underexplored avenue. As discussed in this review,
a number of miRs have been reported to control vascular cell and
stem cell properties that determine vital therapeutic outcomes in VTE.
It may be possible to combine several modulatory strategies to harness
the ‘right’ miR expression signature for a desired clinical beneﬁt. miR
expression levels in vascular cells or progenitor cells could be manipu-
lated in vitro using either an inducible or suicide cassette. This would
allow constitutive expression of miRs and stringent governance of
temporal expression to target dysfunctional gene expression. This may
also open up new alternatives for obtaining autologous cells in a more
time efﬁcient manner for VTE. However, it is important to be careful
with implementing the exciting miR targeting technologies because
a complete understanding of all the processes is still lacking. As a
consequence, miRs have not yet reached clinical application. From a
translational point of view, ex-vivo use of miR targeting for improving
the production and functional properties of cells to be either used for
therapeutic angiogenesis approaches via direct transplantation into is-
chemic tissue or as building blocks for bioengineered scaffolds would
improve the risk proﬁle of any “miR drug”. This would also facilitate
the entrance into the clinical arena via a ﬁrst-in-man clinical trial,
which is now enthusiastically anticipated by the whole community of
basic and clinical scientists whose attention has been captured by miRs.
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